Pfizer director Ronald E. Blaylock acquires $499,072 in stock
Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...
Starboard Value buys Pfizer, exits Humana in Q4
Jeffrey Smith’s Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund’s new buys during the fourth quarter ...
Are Investors Being Too Paranoid About Pfizer Stock?
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
Pfizer Receives Expanded FDA Approval for Cancer Treatment
The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.
Pfizer: 3 Key Risks That Warrant A Sell
Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...
Pfizer's Options Frenzy: What You Need to Know
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
This 7.6% Dividend Can Protect Your Wealth From A Trade War
Trade tensions ratcheted up to 11 this week, and I know that for many readers the wild swings we’re seeing can feel sickening ...
Pfizer: Challenges Loom Amid Overvaluation
Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...
Better High-Yield Dividend Stock: Pfizer vs. Merck
At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...
3 Dividend Stocks to Double Up on Right Now
AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...
Why Pfizer (PFE) Is Declining?
We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...